Abstract
Background: Mucous membrane pemphigoid (MMP) is a rare chronic autoimmune subepithelial blistering disease characterized by predominant oral mucosal involvement and a risk of irreversible scarring affecting multiple mucosal sites. Although conventional immunosuppressive therapy remains the cornerstone of treatment, refractory disease, relapses, and treatment-related toxicity have prompted increasing interest in biologic therapies. This review summarizes the current evidence regarding biologic agents for MMP, with particular focus on patients with oral involvement. Methods: A narrative review of the available literature was conducted, including retrospective studies, case series, and case reports evaluating biologic therapies in MMP. Evidence regarding rituximab, Janus kinase (JAK) inhibitors, anti-tumor necrosis factor-α (TNF-α) agents, dupilumab and omalizumab was critically reviewed. Results: Rituximab is supported by the strongest clinical evidence, consistently achieving high rates of disease control and complete remission in severe or refractory MMP. Emerging evidence indicates that JAK inhibitors may represent a promising targeted therapeutic option, with rapid and sustained clinical responses reported in both retrospective studies and individual cases. Anti-TNF-α agents, particularly etanercept, have demonstrated favorable outcomes in isolated reports, whereas evidence for adalimumab remains limited. Dupilumab and omalizumab have shown encouraging preliminary results, although current evidence is restricted to a few patients. Conclusions: Biologic therapies are expanding the therapeutic options for refractory oral MMP. Rituximab currently represents the best-supported biologic treatment, with evidence from relatively large retrospective cohorts, whereas JAK inhibitors appear particularly promising, despite the limited data available from small case series and case reports. Evidence supporting other biologic agents remains even more limited, highlighting the need for prospective multicenter studies to establish their long-term efficacy, safety, and optimal positioning in the management of MMP.
Keywords:
mucous membrane pemphigoid; oral; therapy; biologic; rituximab; JAK inhibitors; anti-TNF α agents; dupilumab; omalizumab